184 related articles for article (PubMed ID: 21179404)
1. Equivalence of ELISpot assays demonstrated between major HIV network laboratories.
Gill DK; Huang Y; Levine GL; Sambor A; Carter DK; Sato A; Kopycinski J; Hayes P; Hahn B; Birungi J; Tarragona-Fiol T; Wan H; Randles M; Cooper AR; Ssemaganda A; Clark L; Kaleebu P; Self SG; Koup R; Wood B; McElrath MJ; Cox JH; Hural J; Gilmour J
PLoS One; 2010 Dec; 5(12):e14330. PubMed ID: 21179404
[TBL] [Abstract][Full Text] [Related]
2. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
Boaz MJ; Hayes P; Tarragona T; Seamons L; Cooper A; Birungi J; Kitandwe P; Semaganda A; Kaleebu P; Stevens G; Anzala O; Farah B; Ogola S; Indangasi J; Mhlanga P; Van Eeden M; Thakar M; Pujari A; Mishra S; Goonetilleke N; Moore S; Mahmoud A; Sathyamoorthy P; Mahalingam J; Narayanan PR; Ramanathan VD; Cox JH; Dally L; Gill DK; Gilmour J
Clin Vaccine Immunol; 2009 Feb; 16(2):147-55. PubMed ID: 19091991
[TBL] [Abstract][Full Text] [Related]
3. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.
Dubey S; Clair J; Fu TM; Guan L; Long R; Mogg R; Anderson K; Collins KB; Gaunt C; Fernandez VR; Zhu L; Kierstead L; Thaler S; Gupta SB; Straus W; Mehrotra D; Tobery TW; Casimiro DR; Shiver JW
J Acquir Immune Defic Syndr; 2007 May; 45(1):20-7. PubMed ID: 17310936
[TBL] [Abstract][Full Text] [Related]
4. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
[TBL] [Abstract][Full Text] [Related]
5. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.
Cox JH; Ferrari G; Kalams SA; Lopaczynski W; Oden N; D'souza MP;
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):68-81. PubMed ID: 15665646
[TBL] [Abstract][Full Text] [Related]
6. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
Mwau M; McMichael AJ; Hanke T
AIDS Res Hum Retroviruses; 2002 Jun; 18(9):611-8. PubMed ID: 12079556
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.
Samri A; Durier C; Urrutia A; Sanchez I; Gahery-Segard H; Imbart S; Sinet M; Tartour E; Aboulker JP; Autran B; Venet A;
Clin Vaccine Immunol; 2006 Jun; 13(6):684-97. PubMed ID: 16760328
[TBL] [Abstract][Full Text] [Related]
8. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.
Kierstead LS; Dubey S; Meyer B; Tobery TW; Mogg R; Fernandez VR; Long R; Guan L; Gaunt C; Collins K; Sykes KJ; Mehrotra DV; Chirmule N; Shiver JW; Casimiro DR
AIDS Res Hum Retroviruses; 2007 Jan; 23(1):86-92. PubMed ID: 17263637
[TBL] [Abstract][Full Text] [Related]
9. The role of IFN-gamma Elispot assay in HIV vaccine research.
Streeck H; Frahm N; Walker BD
Nat Protoc; 2009; 4(4):461-9. PubMed ID: 19282851
[TBL] [Abstract][Full Text] [Related]
10. Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials.
Moodie Z; Huang Y; Gu L; Hural J; Self SG
J Immunol Methods; 2006 Aug; 315(1-2):121-32. PubMed ID: 16959262
[TBL] [Abstract][Full Text] [Related]
11. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring--even in hands of ELISPOT-inexperienced investigators.
Zhang W; Caspell R; Karulin AY; Ahmad M; Haicheur N; Abdelsalam A; Johannesen K; Vignard V; Dudzik P; Georgakopoulou K; Mihaylova A; Silina K; Aptsiauri N; Adams V; Lehmann PV; McArdle S
J Immunotoxicol; 2009 Dec; 6(4):227-34. PubMed ID: 19908941
[TBL] [Abstract][Full Text] [Related]
12. Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials.
Hudgens MG; Self SG; Chiu YL; Russell ND; Horton H; McElrath MJ
J Immunol Methods; 2004 May; 288(1-2):19-34. PubMed ID: 15183082
[TBL] [Abstract][Full Text] [Related]
13. Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses.
Dintwe OB; De Rosa SC; Huang Y; Flach BS; Manso B; Carter D; Omar FL; Schwedhelm KV; Yu C; Lu H; Morris D; Kee JJ; Voillet V; Stirewalt M; Hural J; Moodie Z; Frahm N; Cohen KW; McElrath MJ; Andersen-Nissen E
J Leukoc Biol; 2022 Nov; 112(5):1167-1181. PubMed ID: 35866359
[TBL] [Abstract][Full Text] [Related]
14. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.
Shafer-Weaver K; Rosenberg S; Strobl S; Gregory Alvord W; Baseler M; Malyguine A
J Immunother; 2006; 29(3):328-35. PubMed ID: 16699376
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.
McElrath MJ; De Rosa SC; Moodie Z; Dubey S; Kierstead L; Janes H; Defawe OD; Carter DK; Hural J; Akondy R; Buchbinder SP; Robertson MN; Mehrotra DV; Self SG; Corey L; Shiver JW; Casimiro DR;
Lancet; 2008 Nov; 372(9653):1894-1905. PubMed ID: 19012957
[TBL] [Abstract][Full Text] [Related]
16. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.
Sambor A; Garcia A; Berrong M; Pickeral J; Brown S; Rountree W; Sanchez A; Pollara J; Frahm N; Keinonen S; Kijak GH; Roederer M; Levine G; D'Souza MP; Jaimes M; Koup R; Denny T; Cox J; Ferrari G
J Immunol Methods; 2014 Jul; 409():107-16. PubMed ID: 24787274
[TBL] [Abstract][Full Text] [Related]
17. International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.
Ozaki DA; Gao H; Todd CA; Greene KM; Montefiori DC; Sarzotti-Kelsoe M
PLoS One; 2012; 7(1):e30963. PubMed ID: 22303476
[TBL] [Abstract][Full Text] [Related]
18. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.
Baden LR; Blattner WA; Morgan C; Huang Y; Defawe OD; Sobieszczyk ME; Kochar N; Tomaras GD; McElrath MJ; Russell N; Brandariz K; Cardinali M; Graham BS; Barouch DH; Dolin R;
J Infect Dis; 2011 Nov; 204(10):1541-9. PubMed ID: 21940420
[TBL] [Abstract][Full Text] [Related]
19. Statistical evaluation of HIV vaccines in early clinical trials.
Moodie Z; Rossini AJ; Hudgens MG; Gilbert PB; Self SG; Russell ND
Contemp Clin Trials; 2006 Apr; 27(2):147-60. PubMed ID: 16426900
[TBL] [Abstract][Full Text] [Related]
20. Proficiency tests to evaluate the impact on assay outcomes of harmonized influenza-specific Intracellular Cytokine Staining (ICS) and IFN-ɣ Enzyme-Linked ImmunoSpot (ELISpot) protocols.
Waerlop G; Leroux-Roels G; Pagnon A; Begue S; Salaun B; Janssens M; Medaglini D; Pettini E; Montomoli E; Gianchecchi E; Lambe T; Godfrey L; Bull M; Bellamy D; Amdam H; Bredholt G; Cox RJ; Clement F
J Immunol Methods; 2023 Dec; 523():113584. PubMed ID: 37918618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
